PT2621496E - Conjugado naloxol-peg cristalino - Google Patents

Conjugado naloxol-peg cristalino Download PDF

Info

Publication number
PT2621496E
PT2621496E PT118296862T PT11829686T PT2621496E PT 2621496 E PT2621496 E PT 2621496E PT 118296862 T PT118296862 T PT 118296862T PT 11829686 T PT11829686 T PT 11829686T PT 2621496 E PT2621496 E PT 2621496E
Authority
PT
Portugal
Prior art keywords
peg conjugate
naloxol
crystalline
crystalline naloxol
conjugate
Prior art date
Application number
PT118296862T
Other languages
English (en)
Inventor
Tesfai Sebhatu
Bengt Leonard Aslund
Carl-Johan Aurell
Martin Hans Bohlin
Bo Ingvar Ymén
Eric Thomas Healy
David Richard Jensen
David Thomas Jonaitis
Stephan Parent
Original Assignee
Astrazeneca Ab
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45893441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2621496(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Nektar Therapeutics filed Critical Astrazeneca Ab
Publication of PT2621496E publication Critical patent/PT2621496E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04Salts; Organic complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
PT118296862T 2010-09-30 2011-09-29 Conjugado naloxol-peg cristalino PT2621496E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38850110P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
PT2621496E true PT2621496E (pt) 2016-02-01

Family

ID=45893441

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118296862T PT2621496E (pt) 2010-09-30 2011-09-29 Conjugado naloxol-peg cristalino

Country Status (39)

Country Link
US (2) US9012469B2 (pt)
EP (2) EP2992903B8 (pt)
JP (1) JP6034789B2 (pt)
KR (1) KR101791724B1 (pt)
CN (1) CN103237547B (pt)
AR (1) AR083268A1 (pt)
AU (1) AU2011307608B8 (pt)
BR (1) BR112013007113B1 (pt)
CA (1) CA2812649C (pt)
CL (1) CL2013000866A1 (pt)
CO (1) CO6700851A2 (pt)
CR (1) CR20130146A (pt)
CU (1) CU24317B1 (pt)
DK (1) DK2621496T4 (pt)
EA (1) EA023929B1 (pt)
EC (1) ECSP13012531A (pt)
ES (2) ES2819305T3 (pt)
GT (1) GT201300084A (pt)
HK (1) HK1187248A1 (pt)
HR (1) HRP20151420T4 (pt)
HU (1) HUE026726T2 (pt)
IL (1) IL225308A0 (pt)
ME (1) ME02313B (pt)
MX (1) MX2013003587A (pt)
MY (1) MY173890A (pt)
NI (1) NI201300034A (pt)
NZ (1) NZ609874A (pt)
PE (1) PE20140636A1 (pt)
PL (1) PL2621496T5 (pt)
PT (1) PT2621496E (pt)
RS (1) RS54488B8 (pt)
SA (1) SA111320808B1 (pt)
SG (1) SG188474A1 (pt)
SI (1) SI2621496T2 (pt)
SM (1) SMT201600004B (pt)
TW (1) TWI518088B (pt)
UA (1) UA112847C2 (pt)
UY (1) UY33643A (pt)
WO (1) WO2012044243A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24317B1 (es) 2010-09-30 2018-02-08 Astrazeneca Ab Conjugado de naloxol-peg cristalino
CN110615796A (zh) * 2012-10-30 2019-12-27 尼克塔治疗公司 作为阿片激动剂的α-6-mPEG6-O-羟基可酮的固体盐形式以及其用途
US10406152B2 (en) * 2015-03-10 2019-09-10 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
CN107033154B (zh) 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN107033155B (zh) * 2016-02-04 2019-04-26 国药集团国瑞药业有限公司 一种吗啡酮类化合物的立体选择性还原方法
EP3228307A1 (en) 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CN107303392A (zh) * 2016-04-19 2017-10-31 石家庄蒎格医药科技有限公司 一种聚乙二醇-纳洛酮组合物及应用
EP3544590A4 (en) * 2016-11-23 2020-10-28 Aurobindo Pharma Limited NALOXEGOL OXALATE AND SOLID DISPERSION OF IT
US11373198B2 (en) * 2016-12-02 2022-06-28 Honda Motor Co., Ltd. Evaluation device, evaluation method, and evaluation program
WO2019058387A1 (en) * 2017-09-19 2019-03-28 Msn Laboratories Private Limited, R&D Center IMPROVED PROCESS FOR THE PREPARATION OF (5Α, 6Α) -17-ALLYL-6- (2,5,8,11,14,17,20-HEPTAOXADOCOSAN-22-YLOXY) -4,5-EPOXYMORPHINANE-3,14-DIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
CN114137133B (zh) * 2021-12-03 2023-06-09 北京尚修堂医药科技有限公司 一种纳洛醇-peg衍生物有关物质的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507136A (en) 1949-02-19 1950-05-09 New York Quinine And Chemical Alkaloid purification
JPH08504189A (ja) * 1992-09-21 1996-05-07 キン、ボーイ 低/非たんでき性オピオイド鎮痛剤の確認及び使用方法
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
EP1355671A2 (en) 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
CN1310912C (zh) 2000-12-22 2007-04-18 史密丝克莱恩比彻姆有限公司 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮甲磺酸盐
MXPA03007392A (es) 2001-02-20 2003-12-04 Enzon Inc Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos.
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
JP4814488B2 (ja) 2001-10-18 2011-11-16 ネクター セラピューティックス 重合体共役物オピオイドアンタゴニスト
MXPA04004026A (es) 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
JP2005507934A (ja) 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル,コーポレイション レチノイン酸の水溶性ポリマー結合体
CA2478523A1 (en) * 2002-04-05 2003-10-16 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
KR20060120141A (ko) 2003-11-24 2006-11-24 네오스 테크놀로지스, 인크. 글리코페질화 에리트로포이에틴
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN102895666B (zh) 2003-12-16 2015-08-19 尼克塔治疗公司 化学改性的小分子
US8320574B2 (en) * 2006-04-20 2012-11-27 Hewlett-Packard Development Company, L.P. Methods and systems for reducing acoustic echoes in communication systems
WO2007124114A2 (en) 2006-04-21 2007-11-01 Nektar Therapeutics Al, Corporation Stereoselective reduction of a morphinone
EA201100544A1 (ru) * 2006-11-07 2012-01-30 Нектар Терапьютикс Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
MX2010011727A (es) * 2008-05-07 2010-11-30 Nektar Therapeutics Administracion oral de antagonistas opioides que actuan perifericamente.
CN102573918A (zh) 2009-07-21 2012-07-11 尼克塔治疗公司 低聚物-阿片样激动剂轭合物
CU24317B1 (es) 2010-09-30 2018-02-08 Astrazeneca Ab Conjugado de naloxol-peg cristalino

Also Published As

Publication number Publication date
SI2621496T2 (sl) 2019-04-30
PE20140636A1 (es) 2014-06-18
RS54488B1 (en) 2016-06-30
AR083268A1 (es) 2013-02-13
CR20130146A (es) 2013-05-15
AU2011307608A8 (en) 2015-08-27
US20150038524A1 (en) 2015-02-05
EA201300423A1 (ru) 2013-09-30
GT201300084A (es) 2015-01-16
PL2621496T5 (pl) 2019-05-31
HRP20151420T1 (hr) 2016-01-29
ES2819305T3 (es) 2021-04-15
EP2621496A1 (en) 2013-08-07
SG188474A1 (en) 2013-05-31
ES2819305T8 (es) 2022-05-26
BR112013007113B1 (pt) 2020-09-24
DK2621496T3 (en) 2016-01-18
US9149539B1 (en) 2015-10-06
CA2812649C (en) 2016-03-01
JP6034789B2 (ja) 2016-11-30
EP2992903B1 (en) 2020-07-15
CN103237547B (zh) 2015-10-07
SI2621496T1 (sl) 2016-02-29
EP2621496B1 (en) 2015-12-16
ES2562643T5 (es) 2019-05-24
TW201307356A (zh) 2013-02-16
MY173890A (en) 2020-02-26
SA111320808B1 (ar) 2014-12-15
CN103237547A (zh) 2013-08-07
AU2011307608B2 (en) 2015-04-09
EP2992903A1 (en) 2016-03-09
CL2013000866A1 (es) 2013-08-30
PL2621496T3 (pl) 2016-05-31
TWI518088B (zh) 2016-01-21
CA2812649A1 (en) 2012-04-05
BR112013007113A2 (pt) 2017-07-25
UA112847C2 (uk) 2016-11-10
NZ609874A (en) 2014-10-31
KR101791724B1 (ko) 2017-10-30
RS54488B8 (sr) 2022-11-30
IL225308A0 (en) 2013-06-27
HK1187248A1 (zh) 2014-04-04
KR20130135844A (ko) 2013-12-11
JP2013538849A (ja) 2013-10-17
AU2011307608B8 (en) 2015-08-27
CO6700851A2 (es) 2013-06-28
UY33643A (es) 2012-04-30
US9012469B2 (en) 2015-04-21
ECSP13012531A (es) 2013-06-28
DK2621496T4 (en) 2019-03-18
ES2562643T3 (es) 2016-03-07
ME02313B (me) 2016-06-20
CU24317B1 (es) 2018-02-08
EP2621496A4 (en) 2014-09-24
US20150283257A1 (en) 2015-10-08
EP2992903B8 (en) 2022-06-08
HUE026726T2 (en) 2016-07-28
HRP20151420T4 (hr) 2019-04-05
AU2011307608A1 (en) 2013-05-02
CU20130047A7 (es) 2013-08-29
EP2621496B2 (en) 2018-12-12
SMT201600004B (it) 2016-02-25
ES2562643T8 (es) 2022-07-12
NI201300034A (es) 2014-01-23
MX2013003587A (es) 2013-05-31
KR101791724B9 (ko) 2022-06-16
WO2012044243A1 (en) 2012-04-05
RS54488B2 (sr) 2019-03-29
EA023929B1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
GB201001075D0 (en) Crystalline forms
ZA201105462B (en) Crystalline insulin-conjugates
HK1179833A1 (zh) 護具
HRP20151420T4 (hr) Kristalni konjugat naloksol-peg
HK1182594A1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5-
PL2590974T3 (pl) Pochodne tetrahydropirydo-pirymidyny
DK2786756T3 (en) Kombinationsterapi med en topoisomeraseinhibitor
PL2578595T3 (pl) Krystaliczna lewoizowalerylospiramycyna I
EP2550960A4 (en) SOLID PREPARATION
EP2550961A4 (en) SOLID PREPARATION
GB2490849B (en) Di-aspirin derivatives
HK1174625A1 (en) Pyrrazolopyridine derivatives
HU1000243D0 (en) 8-hidroxy-quinoline derivatives
GB2481646B (en) Agrictultural implement
GB201005703D0 (en) Holders
GB2477321B (en) Holders
GB201009684D0 (en) Odontalgic preparation
GB201004410D0 (en) Split-pair timing
IL222998A0 (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives
TWM387623U (en) Towel improvement